This article is more than 5 years old. Information may no longer be current.

Dosing underway in BioTime dry AMD trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The first patient has been dosed in an ongoing phase 1/2a clinical trial with a new thaw-and-inject formulation of OpRegen, delivered with the Orbit subretinal delivery system, BioTime announced in a press release.

The open-label, dose escalation trial will evaluate the safety and efficacy of OpRegen, a human embryonic stem cell-derived retinal pigment epithelium transplant therapy, in patients with dry age-related macular degeneration.

“We are excited to be evaluating the FDA-cleared Orbit SDS in the next six patients of our phase 1/2a study,” Brian M. Culley, BioTime CEO, said in the release. “We believe that precise administration of OpRegen cells to the back of the eye utilizing the Orbit SDS will lead to better dose control and an overall safer procedure, with an increased likelihood of positive clinical outcomes. In preparation for potential future commercialization, we also are introducing our new thaw-and-inject formulation, enabling rapid off-the-shelf administration of RPE cells upon thawing, which we believe will streamline the use of OpRegen by retinal surgeons.”